Full Text
Introduction of an Infliximab Biosimilar (CT-P13)- A Five-Year Budget Impact Analysis for the Treatment of Rheumatoid Arthritis in Ireland

Abstract

Authors

G. McCarthy C. Ebel Bitoun H. Guy

Back to Volume 16, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×